@inproceedings{inproceedings, title  = {{Adjuvant bevacizumab in patients with melanoma at high
risk of recurrence (AVAST-M): preplanned interim results
from a multicentre, open-label, randomised controlled
phase 3 study}},

 publisher = {{Elsevier}},

 url = {{https://eprints.whiterose.ac.uk/id/eprint/131249 https://doi.org/10.1016/S1470-2045(14)70110-X }},

 year = {{2017}},

 month = {{5}},

 author = {{Corrie P and Marshall A and Dunn J and Middleton MR and Nathan PD and Gore ME and Davidson D and Nicholson S and Kelly CG and Marples M and Danson S et al}},

 doi = {{10.1016/S1470-2045(14)70110-X}},

 volume = {{15}},

 journal = {{Lancet Oncology}},

 issue = {{6}},

 pages = {{620-630}},

 note = {{Accessed on 2025/12/07}}}